title: Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria.
abstract: To evaluate the therapeutic role of cyclosporin A (CyA) for the treatment of Henoch-Schönlein nephritis (HSN), 29 patients (18 boys, 11 girls) with nephrotic-range proteinuria were analyzed retrospectively. Mean age was 8.6 years (range 2.0-15.5 years) at diagnosis of Henoch-Schönlein purpura (HSP). All patients had developed the nephrotic-range proteinuria at a mean interval of 4.4 months (range 0-50.7 months) after the diagnosis of HSP. Mean duration of CyA treatment was 12.3 months (range 2.6-55.0 months). Mean follow-up times were 3.7 years (range 1.2-12.9 years) from the beginning of the CyA treatment. Steroids were tapered off and stopped gradually after initiation of CyA. All patients responded to the CyA treatment within a mean of 1.8 months (range 1 week to 3.5 months). Twenty-three patients achieved stable remission with mean follow-up duration of 3.2 years and 6 patients seemed to become CyA-dependent, since they developed proteinuria when the treatment was stopped. Renal function was preserved in all patients but one who developed end-stage renal disease after poor compliance with CyA. We concluded that CyA treatment for HSN showing nephrotic-range proteinuria is very effective and a safe method, although some patients become CyA-dependent.
authors.affiliation: Department of Pediatrics, Ajou University School of Medicine, 5 Woncheon-Dong, Youngtong-Gu, 442-749, Suwon, Korea.
authors.forename: Jee Min
authors.initials: JM
authors.lastname: Park
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Won
authors.forename: Jae Il
authors.initials: JI
authors.lastname: Shin
authors.forename: Hyunee
authors.initials: H
authors.lastname: Yim
authors.forename: Ki Soo
authors.initials: KS
authors.lastname: Pai
mesh_terms: D000293:Adolescent; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009393:Nephritis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D009404:Nephrotic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011507:Proteinuria / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D056910:Republic of Korea; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine